SLC5A2 and hydrops fetalis: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have emerged as new and widely studied drugs in cardiology because of their positive effects in a wide spectrum of CV and metabolic parameters Recently, SGLT2 inhibitors have been recommended in heart failure (HF) guidelines [4] to reduce cardiovascular mortality and hospitalization caused by HF exacerbations.